Global Thyroid Cancer Drug Market, By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC) and Anaplastic Thyroid Cancer), Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy and Surgery), Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib and Others), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The thyroid cancer drug market is expected to witness market growth at a rate of 21.47% in the forecast period of 2021 to 2028 and is expected to reach USD 3,548.27 million by 2028. Data Bridge Market Research report on thyroid cancer drug market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of thyroid cancer globally is escalating the growth of thyroid cancer drug market.
Thyroid cancer refers to a type of malignant cancer which is initiated from the par follicular and follicular thyroid cells. It is also known as thyroid nodules which occurs in thyroid gland and can spread to other parts of the body and about 90% of all thyroid cancers are benign. Surgical removal of the thyroid gland, radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy are some of the available treatments.
The increase in the rate of neuroendocrine tumor cases among population across the globe acts as one of the major factors driving the growth of thyroid cancer drug market. The rise in investment in the research and development activities to enhance the overall course of diagnosis and treatment of thyroid cancer and growing awareness about treatment and technological advancement accelerate the thyroid cancer drug market growth. The rise in the number of obese population and the adoption of unhealthy lifestyle traits such as consumption of junk food and alcohol further influences the thyroid cancer drug market. Additionally, rise in funds by profit and non-profit organizations for the treatment, surge in healthcare expenditure and government support positively affect the thyroid cancer drug market. Furthermore, increase in the demand of treatment and novel therapies extend profitable opportunities to the thyroid cancer drug market players in the forecast period of 2021 to 2028.
On the other hand, introduction of generic version of branded drugs and high cost associated with the treatment are expected to obstruct the thyroid cancer drug market growth. Lack of skilled professionals and limited awareness in developing nations regarding treatments are projected to challenge the thyroid cancer drug market in the forecast period of 2021-2028.
This thyroid cancer drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on thyroid cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Thyroid Cancer Drug Market Scope and Market Size
The thyroid cancer drug market is segmented on the basis of type, treatment, drug type, route of administration and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the thyroid cancer drug market is segmented into papillary thyroid cancer, follicular thyroid cancer, hurthle cell cancer, medullary thyroid cancer (MTC) and anaplastic thyroid cancer.
- On the basis of treatment, the thyroid cancer drug market is segmented into medication, chemotherapy, radioactive iodine (radioiodine) therapy, hormone therapy and surgery. Surgery is further segmented into lobectomy, near-total thyroidectomy and total thyroidectomy.
- On the basis of drug type, the thyroid cancer drug market is segmented into thyroid desiccated, sorafenib, thyrotropin alfa, vandetanib, doxorubicin, cabozantinib, lenvatini, sodium iodide i-131, dabrafenib, trametinib and others.
- On the basis of route of administration, the thyroid cancer drug market is segmented into oral, injectable and others.
- On the basis of end- users, the thyroid cancer drug market is segmented into hospitals, homecare, specialty clinics and others.
Global Thyroid Cancer Drug Market Country Level Analysis
The thyroid cancer drug market is analyzed and market size information is provided by country, type, treatment, drug type, route of administration and end- users as referenced above.
The countries covered in the global thyroid cancer drug market report are the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the thyroid cancer drug market due to the well-established health coverage and high level of awareness regarding the illness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The thyroid cancer drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to thyroid cancer drug market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the thyroid cancer drug market in the growth period.
Competitive Landscape and Thyroid Cancer Drug Market Share Analysis
The thyroid cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to thyroid cancer drug market.
The major players covered in the thyroid cancer drug market report are Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc. and Vascular Biogenics among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.